Abstract:Maike Delic, Veronika Boeswald, Katrin Goepfert, Petra Pabst, Markus Moehler University Medical Center of the Johannes Gutenberg University Mainz, 1st Department of Internal Medicine, Mainz, Germany Correspondence: Maike Delic, University Medical Center of the Johannes Gutenberg University Mainz, 1st Department of Internal Medicine, Langenbeckstrasse 1, Mainz, 55131, Germany, Tel +49 6131 179803, Fax +49 6131 179657, Email Purpose: We studied the innate and adaptive immune response against melanoma cells after JS-1 (wild-type herpes simplex virus 1, wt HSV-1) or Talimogene laherparepvec (T-VEC) infection and evaluated the antitumoral efficacy in human melanoma cells. We analyzed the putative synergistic biological and immunological effects of JS-1 or T-VEC combined with cytostatic drugs in human tumor and immune cells. T-VEC is a genetically modified strain of HSV-1. Genetic modifications (insertion of the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene) were made to attenuate the virus and increase selectivity for cancer cells. In addition to the direct oncolytic effect, we investigated the immune stimulatory effects of T-VEC by comparing it with JS-1. JS-1 is identical T-VEC except for the inserted GM-CSF gene. Materials and Methods: We analyzed the effects of T-VEC and JS-1 with cytostatic drugs in human tumor-immune cell coculture experiments. After coculture, the surface markers CD80, CD83 and CD86 were measured by fluorescence-activated cell sorting and the cytokines, interleukin (IL)-2, IL-6, tumor necrosis factor (TNF)-α and GM-CSF, by enzyme-linked immunosorbent assays. Furthermore, we analyzed the potential of the viruses to induce T cell activation, measured on the basis of CD4, CD8 and CD69. Analysis of these markers and cytokines allows for conclusions to be drawn concerning the maturation of dendritic cells (DCs) and the immunostimulatory effects of the treatment. Results: We documented increased activation of human cytotoxic T lymphocytes after infection by both HSV-1 strains and treatment with cytostatic drugs without significant differences between T-VEC and JS-1. Conclusion: We demonstrated an immune response as a result of infection with both viruses, but T-VEC was in vitro not stronger than JS-1. The immunostimulatory effects of the viruses could be partially increased by chemotherapy, providing a rationale for future preclinical studies designed to explore T-VEC in combined regimens. Keywords: oncolytic virotherapy, immunotherapy, dendritic cells, T-VEC, immunostimulatory effect Since oncolytic viruses are a relatively new therapeutic method and only two viruses have been approved worldwide so far, their use is mainly limited to clinical studies. 1,2 Compared with conventional tumor therapies such as radiation therapy and poly-chemotherapy, oncolytic viruses are generally better tolerated and safer due to increased tumor specificity. 3 In contrast to targeted therapies, they are not dependent on specific tumor-expressed receptors or antigens, which mean that tumor resistance can be reduced. 4 Current studies follow the principle of combination therapy each having different approaches. The effectiveness in combination with standard therapy should always be checked for new treatment options. An increased response has already been shown for oncolytic viruses when combined with radiation in vitro 5 and valproic acid in vivo and in vitro. 6 Chemotherapeutic agents such as doxorubicin 7 and oxaliplatin 8 showed an induction of immunogenic cell death, which is also induced by oncolytic viruses. A synergistic combination could enable a dose reduction of the cytotoxic agents with consequently fewer side effects. Such synergism has already been proven for the combination of gemcitabine and H-1PV, 9 cisplatin and vaccinia virus GLV-1h68 10 as well as doxorubicin with adenovirus SG511-BECN. 11 The combination treatment of melanoma cells with cisplatin or vincristine and H-1PV also showed an increased maturation of dendritic cells (DCs) with increased cytokine release compared to cytostatic therapy alone. 12 Despite the approved promising immunotherapeutic substances, patients with advanced melanoma are often progressive in course of the disease and can no longer be treated with standard therapies. 13 New, potent combination treatment to reduce the dose without compromising the success of the therapy are needed. A synergistic or at least additive combination treatment with other active substances would be desirable. For example, a spontaneously mutated strain of HSV-1, HF10, showed cytolytic effects after infection in an in vitro study that revealed murine and human melanoma tumor -Abstract Truncated-

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma

Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).

Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis

Advancing oncolytic virus therapy by understanding the biology

Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma

Abstract CT004: A single arm phase 2 study of TVEC in patients with invasive cutaneous SCC: A novel therapeutic approach for low risk tumors

Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.

Abstract B141: Combining the telomerase peptide cancer vaccine UV1 with CTLA-4 blockade in patients with metastatic malignant melanoma: Proof of principle and early clinical reports from a phase I/IIa trial

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival

Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?

Electrochemotherapy of Melanoma Cutaneous Metastases in Organ Transplant Recipients: A Systematic Review of Preclinical and Clinical Studies

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells